Trial Watch No. 11
Where Conviction Is Building, In Real Time
The first half of June 2026 delivers three categorical first-time signals. Imatinib's 23-year monument is challenged for the first time as GSK's Velzatinib enters Phase 3 directly against imatinib in 1L GIST (800 patients). BTK class succession begins; Nurix's NX-5948, the first BTK degrader to reach Phase 3, runs head-to-head against pirtobrutinib in r/r CLL. And AAV gene therapy enters hereditary cardiac disease as Affinia's UPBEAT AFTX-201 becomes the first AAV in clinic for BAG3-mutated dilated cardiomyopathy.
Summary Layer
CAR-T continues its autoimmune sprint. BMS-986353 (zola-cel); last seen in Edition 8 Phase 3 in systemic sclerosis; now opens Phase 2 in chronic ITP plus AIHA. Cabaletta's CABA-201 enters Phase 1/2 in multiple sclerosis. Across four editions the autoimmune CAR-T map now covers SSc; SLE; ITP/AIHA; MS. Big pharma operational capital keeps scaling: APHP's 4,336-patient OHCA epinephrine trial and Regeneron's 1,570-patient Linvoseltamab MM Phase 2/3 mark the third consecutive edition with Phase 3 enrollment over 1,000.
15 high-signal trials across oncology, cardiometabolic, immunology, neurology, and advanced modalities. Each entry is linked to a primary registry record and an official sponsor or study page where available.
Therapeutic Areas Covered
Oncology
6 trialsVelzatinib (GSK6042981) vs. Imatinib in Previously Untreated Metastatic / Unresectable GIST
GSK's next-gen TKI takes on imatinib's 23-year frontline standard in 1L GIST
Timeline
Start: June 15, 2026. Primary completion: August 2032.
Mechanism
Velzatinib is GSK's next-generation tyrosine kinase inhibitor targeting KIT/PDGFRA mutations in GIST. Trial runs head-to-head against imatinib (Gleevec); the standard of care since 2002.
Why It Matters
Imatinib's 23-year dominance in front-line GIST is being directly challenged for the first time. GSK staking 800 patients against a $2B+ legacy franchise signals confidence that Velzatinib delivers superior PFS or covers the resistance mutations imatinib can't. Continues the 2026 head-to-head theme (Roche vs. Hemlibra, Janssen vs. Tremfya, Novo vs. Wegovy, Merck vs. blinatumomab) into one of oncology's oldest standards.
NX-5948 vs. Pirtobrutinib in Relapsed/Refractory CLL/SLL
First BTK degrader in Phase 3 challenges Lilly's pirtobrutinib head-to-head
Timeline
Start: June 2026. Primary completion: October 2029.
Mechanism
NX-5948 is the first oral BTK degrader (chimeric small molecule that recruits E3 ligase to drive proteolytic destruction of BTK) to reach Phase 3. Pirtobrutinib is Lilly's approved non-covalent BTK inhibitor; the most recent generation of inhibitor-class drugs.
Why It Matters
Class succession event. Twenty years of BTK inhibitor evolution (ibrutinib; acalabrutinib; zanubrutinib; pirtobrutinib) culminates in the degrader generation. If NX-5948 wins on durability or resistance mutation coverage (C481S, T474, gatekeeper mutations), the BTK inhibitor era is functionally over. AbbVie, AstraZeneca, BeOne, and Lilly all face existential succession decisions.
Linvoseltamab + Bortezomib + Lenalidomide ± ASCT vs. DVRd; 1L Multiple Myeloma
1,570-patient Phase 2/3 moves BCMAxCD3 BiTE into newly diagnosed, transplant-eligible MM
Timeline
Start: June 5, 2026. Primary completion: May 2038.
Mechanism
Linvoseltamab (Regeneron's approved BCMAxCD3 BiTE) moves from r/r MM into newly diagnosed transplant-eligible patients, replacing daratumumab in the DVRd backbone. The trial also tests whether linvoseltamab obviates the need for autologous stem cell transplant.
Why It Matters
1,570-patient Phase 2/3; Regeneron is moving a BCMA bispecific from salvage to front-line in newly diagnosed MM. The hypothesis: BiTE-driven plasma cell depletion plus IMiD/proteasome inhibitor can eliminate ASCT from the standard regimen, removing a major morbidity burden. If positive, daratumumab-based DVRd loses 1L dominance and ASCT volumes drop globally. Roche's cevostamab (Edition 9 2L MM Ph3) is the parallel bet from the other direction.
Verified sources
Subcutaneous vs. Intravenous Blinatumomab in Newly Diagnosed Ph− B-ALL
Amgen's SC reformulation could end blinatumomab's 28-day infusion pump era
Timeline
Start: June 11, 2026. Primary completion: May 2030.
Mechanism
Subcutaneous reformulation of blinatumomab (CD19xCD3 BiTE) tested against the current IV continuous-infusion standard plus HyperCVAD in newly diagnosed Philadelphia-chromosome-negative B-ALL.
Why It Matters
Blinatumomab's continuous IV infusion has been the franchise's biggest operational limitation since 2014 approval; patients carry infusion pumps for 28 days per cycle. SC reformulation eliminates that burden and potentially shifts care from inpatient to outpatient. The Edition 10 MK-1045 vs. blinatumomab head-to-head was Amgen's external defensive move; this SC Phase 3 is the internal lifecycle move. Both shape the BiTE franchise's next decade.
Verified sources
Obrixtamig + Carboplatin/Etoposide vs. Carboplatin/Etoposide in DLL3+ Extrapulmonary Neuroendocrine Carcinoma
DLL3 BiTE crosses into the first non-SCLC Phase 3 indication
Timeline
Start: June 15, 2026. Primary completion: December 2029.
Mechanism
Obrixtamig is Boehringer's DLL3xCD3 BiTE, run as 1L combination with carboplatin/etoposide in DLL3+ extrapulmonary neuroendocrine carcinoma (Ventana DLL3 RxDx assay for patient selection).
Why It Matters
DLL3 is now a four-modality target. Tarlatamab (Amgen BiTE) approved in SCLC. DJI136 (Novartis CAR-T, Edition 9) in SCLC. [212Pb]Pb-MP0712 (Molecular Partners alpha radiopharm, Edition 10) in DLL3+ solid tumors. Now Boehringer's obrixtamig BiTE Phase 3 in extrapulmonary NEC. Four editions, four DLL3 modality approaches. Extrapulmonary neuroendocrine is the first non-SCLC indication crossing into Phase 3 for the target.
Verified sources
Rinatabart Sesutecan (Rina-S) vs. Investigator's Choice in Platinum-Resistant Ovarian Cancer; China Extension
Genmab's FRα ADC tests a TOPO1 payload against mirvetuximab's class standard
Timeline
Start: June 2026. Primary completion: September 2027.
Mechanism
Rinatabart Sesutecan (Rina-S) is Genmab's FRα-directed antibody-drug conjugate with an exatecan payload. Trial compares Rina-S monotherapy against investigator's choice (paclitaxel, topotecan, PLD, gemcitabine) in platinum-resistant ovarian cancer.
Why It Matters
This 82-participant record is the China extension of Genmab's global Phase 3 RAINFOL-02 program, rather than a separate standalone pivotal strategy. It expands the same Rina-S versus investigator's-choice comparison into China. The parent global trial is NCT06619236. Mirvetuximab remains the established FRα ADC benchmark, while Rina-S tests whether a differentiated TOPO1 payload can create class-level competition.
Cardiometabolic
3 trialsLow-Dose vs. Standard-Dose Epinephrine in Out-of-Hospital Cardiac Arrest
4,336-patient European trial revisits resuscitation dosing for the first time in three decades
Timeline
Start: June 2026. Primary completion: July 2030.
Mechanism
Tests whether 0.5 mg epinephrine IV bolus (half the standard dose) improves neurological outcome at 90 days versus the current 1 mg standard, on the hypothesis that lower-dose epinephrine reduces cerebral microvascular dysfunction during reperfusion.
Why It Matters
Resuscitation epinephrine dosing hasn't been definitively re-tested in three decades. PARAMEDIC-2 (2018) showed standard-dose epinephrine improves ROSC but worsens neurological outcomes; likely from cerebral vasoconstriction. A 4,336-patient European multicenter trial is the largest definitive test of dose reduction yet. A positive result rewrites international ACLS guidelines.
Verified sources
SWITCH; Apixaban vs. Warfarin in HeartMate 3 LVAD Patients
Columbia's pragmatic Phase 3 could end warfarin's era in mechanical circulatory support
Timeline
Start: June 2026. Primary completion: June 2029.
Mechanism
Tests whether apixaban (DOAC) is non-inferior to vitamin K antagonist warfarin in preventing thromboembolic events in patients with HeartMate 3 left ventricular assist devices. Endpoints include LVAD thrombosis, bleeding, stroke, and heart transplant.
Why It Matters
LVAD patients have been stuck on warfarin since the device's inception; chronic INR monitoring, dietary restrictions, narrow therapeutic window. DOACs have replaced VKAs in almost every other indication (atrial fibrillation, DVT/PE) but never in mechanical circulatory support. Columbia (a top US transplant/LVAD center) running a 460-patient pragmatic Phase 3 could end the warfarin era in LVAD therapy if positive.
Verified sources
Treprostinil Palmitil Inhalation Powder; Long-Term OLE in PH-ILD
Insmed's once-daily prostacyclin platform opens its second indication front against Tyvaso
Timeline
Start: June 5, 2026. Primary completion: January 2031.
Mechanism
Long-term open-label extension of treprostinil palmitil inhalation powder (TPIP); Insmed's once-daily inhaled prostacyclin prodrug; in pulmonary hypertension associated with interstitial lung disease. Sister program to Edition 8's PALM-PAH (in PAH).
Why It Matters
PH-ILD is a $1B+ category currently dominated by United Therapeutics' Tyvaso (which won the PH-ILD label in 2021). Insmed's once-daily TPIP threatened United's dosing-convenience moat in PAH (Edition 8); now Insmed is opening the PH-ILD front. Two indications, one inhaled once-daily prostacyclin platform; Insmed's playbook is direct franchise replacement.
Verified sources
Immunology & Autoimmune
1 trialUblituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
TG Therapeutics extends Briumvi into the underserved pediatric RMS segment
Timeline
Start: June 1, 2026. Primary completion: January 2030.
Mechanism
Ublituximab (Briumvi) is TG Therapeutics' anti-CD20 monoclonal antibody, approved in adult RMS in 2022. This pediatric program tests Briumvi vs. fingolimod (active comparator) in adolescents with relapsing MS.
Why It Matters
Pediatric MS is an underserved segment; only fingolimod has the dedicated label. A successful pediatric Briumvi trial extends TG's label, captures a treatment-naive cohort, and positions ublituximab as the only anti-CD20 with both adult and pediatric MS approval. Ocrevus (Roche) has pediatric Phase 3 data pending; this is the competitive race.
Neurology
2 trialsPridopidine in Adults With Huntington's Disease
Prilenia re-tests the sigma-1 agonist with a refined Phase 3 design after PROOF-HD's miss
Timeline
Start: June 2026. Primary completion: June 2028.
Mechanism
Pridopidine is a sigma-1 receptor agonist developed for Huntington's disease; addressing neurodegeneration via ER stress modulation, mitochondrial function, and protein homeostasis rather than HTT-mRNA suppression.
Why It Matters
No disease-modifying therapy has yet achieved regulatory approval in Huntington's disease. Roche's tominersen and Wave's WVE-003 antisense programs have stalled or failed. Pridopidine's PROOF-HD Phase 3 readout in 2023 missed primary endpoint but suggested subgroup signal. Prilenia's re-tested Phase 3; with refined endpoints; is HD's most prominent ongoing program. The disease remains in urgent need of a positive trial.
Verified sources
Masitinib (4.5 mg/kg) as Add-On to Standard of Care in Mild Alzheimer's Disease
AB Science's neuroinflammation-targeted TKI returns for a re-tested Phase 3
Timeline
Start: June 2026. Primary completion: December 2028.
Mechanism
Masitinib is an oral c-Kit/Lyn tyrosine kinase inhibitor targeting mast cell and microglial neuroinflammation; a fundamentally different Alzheimer's mechanism from anti-amyloid antibodies (lecanemab, donanemab) or anti-tau approaches.
Why It Matters
AB Science's previous Alzheimer's Phase 3 (AB09004) hit on ADAS-Cog in mild patients but was rejected by EMA / declined by FDA over methodology concerns. The new Phase 3 is the re-test with revised design. With lecanemab and donanemab dominating commercial conversation, an oral neuroinflammation-targeted asset that works as add-on would carve out a different niche entirely; particularly given the infusion logistics and ARIA monitoring burden of anti-amyloid agents.
Advanced Modalities
3 trialsZolacabtagene Autoleucel (BMS-986353) in Chronic ITP and Autoimmune Hemolytic Anemia
BMS expands its CD19 CAR-T autoimmune platform into hematologic cytopenias
Timeline
Start: June 15, 2026. Primary completion: May 2030.
Mechanism
Same CD19-directed NEX-T CAR-T (zola-cel / BMS-986353) that opened Phase 3 in systemic sclerosis (Breakfree-SSc, Edition 8). Now Phase 2 expansion in chronic immune thrombocytopenia and autoimmune hemolytic anemia; two hematologic autoimmune indications driven by B-cell autoantibody production.
Why It Matters
Fourth autoimmune indication for the BMS CD19 CAR-T platform in three editions. Edition 8 systemic sclerosis Phase 3. Edition 11 ITP + AIHA Phase 2. The autoimmune CAR-T platform breakout is no longer a single-indication bet; it's a category strategy. Argenx (anti-FcRn) and rituximab face new platform-level competition in ITP/AIHA, where existing therapies offer remission but rarely cure.
Verified sources
RESET-MS; CABA-201 CD19 CAR-T in Relapsing and Progressive Multiple Sclerosis
First dedicated CAR-T MS program at a focused-platform sponsor
Timeline
Start: June 2026. Primary completion: September 2028.
Mechanism
Autologous CD19-specific CAR-T (CABA-201) administered as a single dose in both relapsing and progressive MS subtypes. Phase 1 inclusion rationale: first dedicated CAR-T MS program at a focused-platform sponsor; novel autoimmune indication on a validated CD19 target.
Why It Matters
MS is now the fourth autoimmune category in the CAR-T expansion: systemic sclerosis (Edition 8), dermatomyositis (Edition 8), lupus + lupus nephritis (Edition 10 mosunetuzumab BiTE), ITP/AIHA (this edition), and now MS. Anti-CD20 (ocrelizumab, ublituximab) dominates RMS; but progressive MS remains poorly treated. If CAR-T delivers durable progressive-MS remission, the entire MS treatment paradigm shifts from chronic infusion to one-time cellular therapy.
Verified sources
UPBEAT; AFTX-201 AAV Gene Therapy in BAG3-Mutated Dilated Cardiomyopathy
First AAV gene therapy in clinic for a hereditary cardiomyopathy
Timeline
Start: June 2026. Primary completion: December 2028.
Mechanism
AAV-delivered BAG3 gene replacement for patients with BAG3 (BCL2-Associated Athanogene 3) loss-of-function mutations causing dilated cardiomyopathy. BAG3 is a chaperone essential for sarcomere stability; loss-of-function variants cause progressive heart failure in young adults. Phase 1 inclusion: first AAV gene therapy for a hereditary cardiomyopathy; novel modality on a genetically validated target.
Why It Matters
AAV gene therapy reaches its first hereditary cardiac disease. The three-edition arc: NAAVIGATE (AbbVie AAV in diabetic retinopathy, Edition 10); VGN-R08b (Shanghai Vitalgen AAV in GBA1 Parkinson's, Edition 10); AFTX-201 (Affinia AAV in BAG3 DCM, Edition 11). Affinia's TissueTarget AAV platform is the technology differentiator; cardiac tropism beyond standard AAV9. If this works, hereditary HCM (MYBPC3, MYH7) and arrhythmogenic cardiomyopathy (PKP2, DSG2) become tractable AAV targets.
Verified sources
Signal Convergence
Imatinib's 23-year monument is challenged for the first time
GSK's Velzatinib enters Phase 3 directly against imatinib in 1L GIST; the first definitive challenge to imatinib's standard-of-care status since 2002. Continues the broader 2026 head-to-head pattern (Hemlibra, Tukysa, CDK4/6, Tremfya, Wegovy, blinatumomab) into one of oncology's oldest franchise drugs.
BTK class succession arrives
Nurix's NX-5948, the first BTK degrader in Phase 3, runs head-to-head against pirtobrutinib in r/r CLL. Twenty years of BTK inhibitor evolution (ibrutinib; acalabrutinib; zanubrutinib; pirtobrutinib) reaches its next class generation. If degraders win, AbbVie, AstraZeneca, BeOne, and Lilly face existential decisions.
DLL3 becomes a four-modality target
Tarlatamab BiTE (approved). DJI136 CAR-T (Edition 9). [212Pb]Pb-MP0712 alpha radiopharmaceutical (Edition 10). Now Boehringer's Obrixtamig DLL3 BiTE in extrapulmonary NEC (Edition 11). Four editions, four modalities, expanding from SCLC into epNEC. No solid-tumor target has ever assembled this stack depth this quickly.
CAR-T autoimmune sprint extends to its fourth and fifth categories
BMS-986353 (zola-cel) opens Phase 2 in chronic ITP + AIHA. Cabaletta CABA-201 enters Phase 1/2 in MS. Across four editions, the autoimmune CAR-T map covers systemic sclerosis; dermatomyositis; SLE; ITP/AIHA; MS. Five autoimmune categories under platform attack in eight weeks.
AAV gene therapy crosses into hereditary cardiac disease
Affinia's UPBEAT (AFTX-201 in BAG3 DCM) is the first AAV in clinic for hereditary structural heart disease. Three-edition arc: AbbVie NAAVIGATE in DR (Edition 10); Shanghai Vitalgen VGN-R08b in GBA1 PD (Edition 10); Affinia AFTX-201 in BAG3 DCM (Edition 11). Categorical expansion week over week.
Mega-trials continue to scale
APHP's 4,336-patient OHCA epinephrine trial. Regeneron's 1,570-patient Linvoseltamab MM Phase 2/3. Third consecutive edition with a Phase 3 enrollment over 1,000. Big pharma operational capital is firmly back at scale.
On Verification
Each trial entry includes its ClinicalTrials.gov record where publicly available, a WHO ICTRP lookup link, and an official sponsor or study page where available. WHO ICTRP pages can load slowly or time out, so the primary registry and official sponsor or study page should be treated as the main verification layer. Investigator-initiated studies use the registry plus an additional study listing when no dedicated sponsor portal exists. The 15 NCT identifiers in Edition 11 do not overlap with the 17 NCT identifiers listed in Edition 10.
About Trial Watch
Trial Watch is Kitsa's twice-monthly U.S. clinical intelligence briefing. It captures high-signal clinical trial events and interprets where science, capital, and strategy are converging.
Keep exploring
Recommended next
- Blog
11 Early-Phase Trials and Design Frameworks to Reduce Design Risk
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
- Blog
4 AI Misconceptions in Clinical Trials You Cannot Afford to Ignore
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
- Blog
7 Questions to Ask Before Choosing an AI Patient Screening Solution
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
- Glossary
Accelerated Approval
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.